February 16, 2017 — Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the company the right to manufacture [F-18]MK-6240, an early-stage investigational poistron emission tomography (PET) imaging agent. [F-18]MK-6240 is currently being evaluated to image neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Under the terms of its agreement with Cerveau, Siemens’ PETNET Solutions Inc. will initially manufacture [F-18]MK-6240 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional locations.
Siemens’ PETNET Solutions Inc. operates a large network of PET radiopharmaceutical drug manufacturing facilities and dispensing nuclear pharmacies, with over 50 locations worldwide. The company manufactures and dispenses PET radiopharmaceuticals for hospitals, clinics and research facilities worldwide.
For more information: www.usa.healthcare.siemens.com
April 09, 2026 
